Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals

Annals of Gastroenterology

Volumn 28, Issue 1, 2015, Pages 55-65

  Alexopoulou, Alexandra ^a   Karayiannis, Peter ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF NICOSIA MEDICAL SCHOOL   (Cyprus)

Author keywords

Cyclophilin inhibitors; NS5A inhibitors; NS5B polymerase inhibitors; Pegylated interferon plus ribavirin; Protease inhibitors

Indexed keywords

ALISPORIVIR; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; GRAZOPREVIR; INTERLEUKIN 28B; LEDIPASVIR; LOMIBUVIR; MERICITABINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VANIPREVIR; VEDROPREVIR;

AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG RESEARCH; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; GASTROINTESTINAL SYMPTOM; GENE STRUCTURE; GENOME ANALYSIS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS GENOME; VIRUS MUTATION;

EID: 84920410351     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264;214-217.
2. Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
5. Jacobson IM. Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy. Clin Gastroenterol Hepatol 2009;7:921-930.
6. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-463.
7. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19.
8. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007;81:8374-8383.
9. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007;3:e103
10. Appel N, Schaller T, Penin F, Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006;281:9833-9836.
11. Ma Y, Yates J, Liang Y, Lemon SM, Yi M. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol 2008;82:7624-7639.
12. Jones DM, Patel AH, Targett-Adams P, McLauchlan J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol 2009;83:2163-2177.
13. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathol 2008;4:e1000032.
14. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB.; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
15. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777.
16. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-1718.
17. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206.
18. Bühler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012;32(Suppl 1):9-16.
19. Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 2012;8:e1002832.
20. Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007;7:1302-1329.
21. Kwong AD, McNair L, Jacobson I, George S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 2008;8:522-531.
22. Gane EJ, Pockros PJ, Zeuzem S, et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int 2014 doi: 10.1111/liv.12588 [Epub ahead of print].
23. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
24. McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013;58:902-911.
25. Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-2912.
26. Kosaka K, Imamura M, Hayes CN, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat 2014. doi: 10.1111/ jvh.12271 [Epub ahead of print].
27. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014;105:64-71.
28. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor DEBIO-025 combined with PEG IFN-alpha2a significantly reduces viral load in treatment naive hepatitis C patients. Hepatology 2009;49:1460-1468.
29. Patel H, Heathcote EJ. Sustained virological response with 29 days of DEBIO-025 monotherapy in hepatitis C virus genotype 3. Gut 2011;60:879.
30. Flisiak R, Pawlotsky JM, Crabbe R, et al. Once-daily alisporivir (DEB025) plus peginterferon alfa-2a/ribavirin results in superior sustained virologic response in chronic hepatitis C genotype 1 treatment-naive patients. J Hepatol 2011;54(Suppl 1):S2.
31. Jacobson I., McHutchison JG, Dusheiko G, et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
32. Sherman KE, Flamm SL, Afdhal NH, et al.; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
33. Poordad F, McCone J Jr, Bacon BR.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
34. Zeuzem S, Andreone P, Pol S, et al.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
35. Bacon BR, Gordon SC, Lawitz E, RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
36. Vierling JM, Davis M, Flamm S, et al. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol 2014;60:748-756.
37. Buti M, Agarwal K, Horsmans Y, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology 2014;146:744-753.
38. Hézode C, Fontaine H, Dorival C, et al.; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-142.
39. Hézode C, Fontaine H, Dorival C, et al; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-441.
40. Fried MW, Reddy KR, Di Bisceglie AM, et al. HCV-TARGET: A longitudinal, observational study of North American patients with chronic hepatitis C (HCV treated with boceprevir or telaprevir. J Hepatol 2013;58:S335.
41. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. J Hepatol 2014;61:200-209.
42. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58:1918-1929.
43. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-441.
44. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 Who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-1679.
45. Jacobson I., Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.
46. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.
47. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-395.
48. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-2107.
49. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
50. Lawitz E, Poordad F, Brainard D, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides wigh SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013;58:1380A.
51. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013;57:2143-2154.
52. Dieterich D, Asselah T, Guyader D, et al. SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. Antimicrob Agents Chemother 2014;58:3429-3436.
53. Sulkowski MS, Bourlière M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013;57:2155-2163.
54. Jensen D, Asselah T, Dieterich DT, et al. A pooled analysis of two randomized double blind placebo-controlled phase III trials (START Verso 1 and 2) of faldaprevir plus pegylated interferon a-2a and ribavirin in treatment naïve patients with chronic hepatitis C genotype 1 infection background. Hepatology 2013;58:734.
55. Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus pegylated interferon a-2a and ribavirin in chronic HCV genotype 1 treatment naïve patients. Final results from STARTVERSO1 a randomized double blind placebo-controlled phase III trial. J Hepatol 2013;58:S569-S570.
56. Everson G, Cooper C, Hézode C, et al. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ ribavirin in HCV genotypes 1 or 4. Liver Int 2014, doi: 10.1111/liv.12471. [Epub ahead of print].
57. Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-499.
58. Nelson DR, Poordad F, Feld JJ, et al. High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naives and prior relapsers with G1 chronic hepatitis C: CONCISE interim analysis. J Hepatol 2013;58:S362.
59. De luca A, Bianco C, Rossetti B. Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol 2014;18C:9-17.
60. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011;54:1924-1935.
61. Manns MP, Gane E, Rodriguez-Torres M, et al; MK-7009 Protocol 007 Study Group. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. Hepatology 2012;56:884-893.
62. Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol 2013;59:11-17.
63. Rodriguez-Torres M, Stoehr A, Gane EJ, et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol 2014;12:1029-1037.
64. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with Peginterferon alfa-2a and ribavirin in treatment naïve HCV genotype 1 and 4 subjects: phase 2b COMMAND 1 SVR12 results. Hepatology 2012;56:553A-555A.
65. Dore GJ, Lawitz E, Hezode E, et al. Daclatasvir combined with Peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND Gt2/3 study. J Hepatol 2013;58(Suppl 1):S570-S571.
66. Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther 2014;19:501-510.
67. Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014;19:491-499.
68. Bronowicki JP, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013;18:885-893.
69. Gane EJ, Rouzier R, Wiercinska-Drapalo A, et al. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother 2014;58:1136-1145.
70. Marcellin P, Cooper C, Balart L, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013;145:790-800.
71. Manns MP, Vierling JM, Bacon BR, et al. The Combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147:366-376.e6.
72. Pockros PJ, Jensen D, Tsai N, et al. JUMP-C investigators. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha- 2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013;58:514-523.
73. Wedemeyer H, Jensen D, Herring R Jr, et al. PROPEL investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013;58:524-537.
74. Nelson DR, Gane EJ, Jacobson I., et al. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment naïve patients treated for 12 weeks. Zenith study. SVR12 interim analysis. Hepatology 2011;54:S1442.
75. Feld JJ. Jacobson I. Jensen DM. et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir mericitabine and ribavirin +/- peginterferon-alfa-2a in HCV genotype 1-infected partial and null responders: results from the NATTERHORN study. Hepatology 2012;56:S231.
76. Thompson A, Han S, Shiffman MI. et al. GS-5885 + GS-9451 + peginterferon and ribavirin for 6 or 12 weeks achieves high SVR rates in treatment naïve genotype 1 IL28B CC patients. J Hepatol 2013;58:S29.
77. Everson GT, Di Bisceglie AM, Vierling JM, et al. Combination of the NS5A inhibitor, GS-5885, the NS3 protease inhibitor GS-9451 and pegylated interferon plus ribavirin in treatment experienced patients with genotype 1 hepatitis C infection. J Hepatol 2013;58:S6.